196 related articles for article (PubMed ID: 38315450)
1. Integrative analysis confirms TPX2 as a novel biomarker for clinical implication, tumor microenvironment, and immunotherapy response across human solid tumors.
Zhu M; Wang X; Zhang Q; Xie C; Wang T; Shen K; Zhang L; Zhou X
Aging (Albany NY); 2024 Feb; 16(3):2563-2590. PubMed ID: 38315450
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Analysis of the Oncogenic Role of Targeting Protein for Xklp2 (TPX2) in Human Malignancies.
Shao T; Jiang X; Bao G; Li C; Guo C
Dis Markers; 2022; 2022():7571066. PubMed ID: 36304254
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of TPX2-related ceRNA network as prognostic biomarkers in lung adenocarcinoma.
Huo C; Zhang MY; Li R; Zhou XJ; Liu TT; Li JP; Liu X; Qu YQ
Int J Med Sci; 2020; 17(16):2427-2439. PubMed ID: 33029085
[No Abstract] [Full Text] [Related]
4. TPX2 is a novel prognostic marker for the growth and metastasis of colon cancer.
Wei P; Zhang N; Xu Y; Li X; Shi D; Wang Y; Li D; Cai S
J Transl Med; 2013 Dec; 11():313. PubMed ID: 24341487
[TBL] [Abstract][Full Text] [Related]
5. Overexpressed targeting protein for Xklp2 (TPX2) serves as a promising prognostic marker and therapeutic target for gastric cancer.
Liang B; Zheng W; Fang L; Wu L; Zhou F; Yin X; Yu X; Zou Z
Cancer Biol Ther; 2016 Aug; 17(8):824-32. PubMed ID: 27314162
[TBL] [Abstract][Full Text] [Related]
6. TPX2 expression is associated with poor survival in gastric cancer.
Tomii C; Inokuchi M; Takagi Y; Ishikawa T; Otsuki S; Uetake H; Kojima K; Kawano T
World J Surg Oncol; 2017 Jan; 15(1):14. PubMed ID: 28069036
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive pan-cancer analysis reveals NUSAP1 is a novel predictive biomarker for prognosis and immunotherapy response.
Zheng H; Wang M; Zhang S; Hu D; Yang Q; Chen M; Zhang X; Zhang Y; Dai J; Liou YC
Int J Biol Sci; 2023; 19(14):4689-4708. PubMed ID: 37781040
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
9. Integrative analysis based on the cell cycle-related genes identifies TPX2 as a novel prognostic biomarker associated with tumor immunity in breast cancer.
Liu X; Wang W; Chen B; Wang S
Aging (Albany NY); 2024 Apr; 16(8):7188-7216. PubMed ID: 38643462
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and clinical value of Targeting protein for Xenopus kinesin-like protein 2 in patients with gastrointestinal tract cancers: A meta-analysis.
Liu W; Xu J; Zhang C
Medicine (Baltimore); 2018 Nov; 97(46):e13303. PubMed ID: 30431618
[TBL] [Abstract][Full Text] [Related]
11. A systematic pan-cancer analysis identifies LDHA as a novel predictor for immunological, prognostic, and immunotherapy resistance.
Zhang Q; Luo Y; Qian B; Cao X; Xu C; Guo K; Wan R; Jiang Y; Wang T; Mei Z; Liu J; Lv C
Aging (Albany NY); 2024 May; 16(9):8000-8018. PubMed ID: 38709280
[TBL] [Abstract][Full Text] [Related]
12. [miR-218-5p Targeting TPX2 Regulates p53 Pathway and Inhibits Malignant Progression of Lung Adenocarcinoma].
Xu J
Zhongguo Fei Ai Za Zhi; 2023 Oct; 26(10):721-731. PubMed ID: 37989335
[TBL] [Abstract][Full Text] [Related]
13. The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYC.
Takahashi Y; Sheridan P; Niida A; Sawada G; Uchi R; Mizuno H; Kurashige J; Sugimachi K; Sasaki S; Shimada Y; Hase K; Kusunoki M; Kudo S; Watanabe M; Yamada K; Sugihara K; Yamamoto H; Suzuki A; Doki Y; Miyano S; Mori M; Mimori K
Ann Oncol; 2015 May; 26(5):935-942. PubMed ID: 25632068
[TBL] [Abstract][Full Text] [Related]
14. TPX2-p53-GLIPR1 regulatory circuitry in cell proliferation, invasion, and tumor growth of bladder cancer.
Yan L; Li Q; Yang J; Qiao B
J Cell Biochem; 2018 Feb; 119(2):1791-1803. PubMed ID: 28799673
[TBL] [Abstract][Full Text] [Related]
15. TPX2 is a prognostic marker and contributes to growth and metastasis of human hepatocellular carcinoma.
Huang Y; Guo W; Kan H
Int J Mol Sci; 2014 Oct; 15(10):18148-61. PubMed ID: 25302620
[TBL] [Abstract][Full Text] [Related]
16. TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma.
Glaser ZA; Love HD; Guo S; Gellert L; Chang SS; Herrell SD; Barocas DA; Penson DF; Cookson MS; Clark PE
Urol Oncol; 2017 May; 35(5):286-293. PubMed ID: 28108243
[TBL] [Abstract][Full Text] [Related]
17. GLIPR2: a potential biomarker and therapeutic target unveiled - Insights from extensive pan-cancer analyses, with a spotlight on lung adenocarcinoma.
Lin W; Zhang S; Gu C; Zhu H; Liu Y
Front Immunol; 2024; 15():1280525. PubMed ID: 38476239
[TBL] [Abstract][Full Text] [Related]
18. TPX2 overexpression in medullary thyroid carcinoma mediates TT cell proliferation.
Yang X; Liu G; Xiao H; Yu F; Xiang X; Lu Y; Li W; Liu X; Li S; Shi Y
Pathol Oncol Res; 2014 Jul; 20(3):641-8. PubMed ID: 24488334
[TBL] [Abstract][Full Text] [Related]
19. TPX2 promotes cell proliferation and migration via PLK1 in OC.
Ma S; Rong X; Gao F; Yang Y; Wei L
Cancer Biomark; 2018; 22(3):443-451. PubMed ID: 29865033
[TBL] [Abstract][Full Text] [Related]
20. TPX2 Promotes Metastasis and Serves as a Marker of Poor Prognosis in Non-Small Cell Lung Cancer.
Zhou F; Wang M; Aibaidula M; Zhang Z; Aihemaiti A; Aili R; Chen H; Dong S; Wei W; Maimaitiaili A
Med Sci Monit; 2020 Aug; 26():e925147. PubMed ID: 32748897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
